Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood (2025) 146 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2025-1532

Published: 2025

Journal Articles

Dysregulation of NF-kb and p73 signal axes in chronic lymphocytic leukemia with gain-of-function mutated p53

Samon Benrashid, Britten Gordon, Andrew Mitchell, Alexander He, Tzung-Huei Lai, Shrilekha Misra, Shanmugapriya Thangavadivel, Kerry Rogers, Deepa Sampath, Jennifer Woyach

Blood (2025) 146 (Supplement 1): 7405.

https://doi.org/10.1182/blood-2025-7405

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Blood (2025) 146 (Supplement 1): 89.

https://doi.org/10.1182/blood-2025-89

Published: 2025

Journal Articles

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Roberta S. Azevedo, Caitlin Rausch, Alexis Geppner, Francisco Vega, Deepa Sampath, Alessandra Ferrajoli, Kelly Chien, Elias Jabbour, Danielle Hammond, Nicholas Short, Koichi Takahashi, Nitin Jain, Jan Burger, Gautam Borthakur, William Wierda, Chitra Hosing, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2025-3653

Published: 2025

Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Blood (2024) 144 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2024-208159

Published: 2024

Journal Articles

Multiomic Single Cell Profiling Identifies Drivers of Progression in T-Cell Prolymphocytic Leukemia

Vishakha Anand Pawar, Arnau Peris Cuesta, Akanksha Aradhya, Claudia Kettlun, Swaminathan P Iyer, Sachet Shukla, Tapan M. Kadia, Francisco Vega, Deepa Sampath

Blood (2024) 144 (Supplement 1): 6230.

https://doi.org/10.1182/blood-2024-208729

Published: 2024

Journal Articles

Venetoclax As a Combination Partner with NAMPT Inhibitor Rpt-1G for T-ALL

John R. Sanchez, II, Daisy Y. Diaz Rohena, Charmelle D. Williams, Valerio Ciaurro, Min Wu, Francis Roushar, Dennise A. De Jesús-Díaz, Gregory Crimmins, Vinay Puduvalli, Francisco Vega, Palaniraja Thandapani, Deepa Sampath

Blood (2024) 144 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2024-208190

Published: 2024

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2024-203522

Published: 2024

Journal Articles

TP53 Gain-of-Function Mutants Display Unique Transcriptional Profiles in Chronic Lymphocytic Leukemia

Charmelle D. Williams, Suresh Satpati, Janani Ravikrishnan, Bailey Slawin, Daisy Y. Diaz Rohena, Palaniraja Thandapani, Kerry A. Rogers, Seema A. Bhat, Kunal Rai, Jennifer A. Woyach, Deepa Sampath

Blood (2024) 144 (Supplement 1): 6757.

https://doi.org/10.1182/blood-2024-199814

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo

Claudia Kettlun, Daniel Galvan, Jie Xu, Tania P Sainz Zuniga, Sebastian Juarez-Casillas, Daisy Y. Diaz Rohena, Vishal Sahu, Juan Andres Donoso, Arrate Zubero, Estela Rojas-Neira, David Blake, Jared Henderson, Michael Green, Tapan M. Kadia, Deepa Sampath, Francisco Vega

Blood (2024) 144 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2024-193372

Published: 2024

Journal Articles

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Daisy Diaz Rohena, Arnau Peris Cuesta, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Charmelle Williams, Wanyi Hu, Peiyi Zhang, Philip Thompson, William G. Wierda, Nitin Jain, Sachet Shukla, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2023-188250

Published: 2023

Journal Articles

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Anna Skwarska, Vinitha Mary Kuruvilla, Qi Zhang, Sovira Chaudhry, Naval Daver, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Deepa Sampath, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2023-187018

Published: 2023

Journal Articles

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 2260.

https://doi.org/10.1182/blood-2023-182024

Published: 2023

Journal Articles

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Vishakha Anand Pawar, Akanksha Aradhya, Daniel Galvan, Gautam Borthakur, Swami P. Iyer, Mark Kirschbaum, David Blake, Tapan M. Kadia, Deepa Sampath, Francisco Vega

Blood (2023) 142 (Supplement 1): 4192.

https://doi.org/10.1182/blood-2023-178256

Published: 2023

Journal Articles

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood (2023) 142 (Supplement 1): 416.

https://doi.org/10.1182/blood-2023-178259

Published: 2023

Journal Articles

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

Jyotsana Singh, John R. Sanchez II, Chaomei Liu, Bailey Slawin, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, James S. Blachly, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2023-189378

Published: 2023

Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 497–498.

https://doi.org/10.1182/blood-2022-168345

Published: 2022

Journal Articles

MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL

Jyotsana Singh, Daisy Diaz Rohena, Chaomei Liu, Bailey Slawin, Janani Ravikrishnan, Nitin Jain, William G. Wierda, Kai Zhang, Michael Niesman, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 9857–9858.

https://doi.org/10.1182/blood-2022-168391

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Dysregulation of NF-kb and p73 signal axes in chronic lymphocytic leukemia with gain-of-function mutated p53

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Multiomic Single Cell Profiling Identifies Drivers of Progression in T-Cell Prolymphocytic Leukemia

Venetoclax As a Combination Partner with NAMPT Inhibitor Rpt-1G for T-ALL

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

TP53 Gain-of-Function Mutants Display Unique Transcriptional Profiles in Chronic Lymphocytic Leukemia

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

MS-553 Therapy Inhibits BCR Signaling and Increases Survival Dependence on BCL-2 in BTK-Inhibitor Resistant CLL

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only